GET DAILY SIGNALSMyriad Genetics (MYGN): Can Shares Climb +40% to the $8 Target?
Key Takeaways
- The central $8 target is a single, publicly discussed price objective from Craig-Hallum, not a consensus figure; the average of current analyst targets is near $4, below the share price.
- Shares traded near $5.70 in October 2026 after Myriad announced the sale of its prenatal health testing business to Labcorp, up from a $4.21 prior close.
- Reaching $8 would require roughly 40% upside from recent levels, a very large move.
- The analyst range is unusually wide, from $2 (Piper Sandler) to $8 (Craig-Hallum), reflecting deep disagreement about the company's direction.
- Key supports include the prenatal divestiture's expected boost to growth and margins; key risks include repeated guidance cuts and weak prenatal testing volumes.
Where the $8 Target Originates
Myriad Genetics, Inc. (MYGN) is a Salt Lake City-based molecular diagnostics and precision-medicine company known for hereditary cancer, oncology, and pharmacogenomics tests. Because most current analyst targets sit at or below the recent share price, an analyst-derived central target was not usable under the 10% minimum-distance test. The $8 figure therefore comes from public discussion rather than a consensus: it is the price objective set by Craig-Hallum analyst John Wilkin, who on October 2, 2026 raised the firm's target from $4 to $8 while maintaining a Buy rating.
For context, the verified individual targets reviewed span a wide range — Piper Sandler at $2, Wells Fargo and Stephens at $3, UBS at $3.60, Bank of America at $4, TD Cowen at $4.50, and Craig-Hallum at $8 — producing a mean near $4.00, consistent with MarketBeat's independently reported average of $4.02. The gap between that sub-$4 consensus and the $8 objective underscores how divergent views on Myriad have become. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Moves and the Road to $8
Following the October 2026 announcement that Myriad will sell its Prenatal Health testing business to Labcorp Holdings Inc. (LH) for $210 million in cash plus inventory value, shares surged roughly 35% to trade near $5.70, from a $4.21 prior close. Reaching $8 would require an additional gain of about 40%, a very large move for a company that has spent the past year resetting expectations.
The path is complicated by a weak fundamental backdrop. In its second-quarter 2026 report, Myriad lowered full-year revenue guidance to $770 million–$790 million from $860 million–$880 million, citing lower prenatal testing volumes, while quarterly revenue of $190.7 million fell short of estimates and the company posted a larger-than-expected adjusted loss. The divestiture removes a declining segment and bolsters the balance sheet, but it also removes a meaningful revenue stream the company must replace with growth in its core oncology and diagnostics franchise.
Potential Catalysts for Reaching the Target
- The prenatal sale is expected to be accretive to revenue growth and gross margin, and Craig-Hallum cited the divestiture as a primary catalyst for its $8 target.
- Approximately $210 million in cash, roughly half of the company's pre-announcement market capitalization, materially strengthens the balance sheet and could fund strategic reinvestment.
- Core offerings such as hereditary cancer risk testing and pharmacogenomics retain large addressable markets and established reimbursement relationships.
- If management maintains or slightly exceeds third-quarter guidance on the November 4, 2026 call, sentiment could improve quickly given how depressed expectations have become.
Risks That Could Hold Back the Stock
- Sell-side sentiment remains cautious: most recent targets sit at or below the share price, with Piper Sandler's downgrade to Underweight and a $2 target reflecting deep concern.
- Prenatal testing revenue declined 16% year over year in the second quarter, contributing to a guidance cut and persistent uncertainty about volume and reimbursement trends.
- The company is not yet consistently profitable, and traditional valuation tools such as the P/E (price-to-earnings) ratio are not useful while earnings are negative.
- Competition in genetic testing is intense, and losing the prenatal portfolio removes a product line that, while declining, still contributed meaningful volume and clinician relationships.
Charting the Technical Picture
Technically, the shares have been volatile, with a 52-week range of $2.74 to $8.50 and a beta near 1.64. The $8 objective sits just below the November 2025 52-week high of $8.50, an area that could act as overhead resistance. The stock's 50-day and 200-day moving averages, near $3.68 and $4.36 respectively, remain well below current levels, indicating the recent rally has moved shares far above their longer-term trend — a structure that can support momentum but also leaves limited nearby support if sentiment reverses. From what I see, this setup warrants close monitoring of any pullbacks.
Key Dates and Metrics to Watch
Individual price objectives typically reflect a roughly 12-month research horizon, though Craig-Hallum framed its $8 target in the context of the next several quarters of execution. Investors should watch the November 4, 2026 third-quarter results and guidance, any update on the Labcorp transaction's expected close in early 2027, analyst target revisions after the divestiture, and whether core oncology and diagnostics volumes can offset the loss of prenatal revenue. Balance-sheet deployment of the sale proceeds will also be a key signal. I'm watching this closely ahead of the earnings release.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, heavily debated name like Myriad Genetics, traders can use these signals to discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening allows. Explore the AI Daily Buy/Sell Signals to see how AI-driven monitoring can support your own decision-making process.
My Take on the Outlook
Whether Myriad Genetics can reach $8 depends on whether the prenatal divestiture genuinely transforms the company's growth and margin profile, as Craig-Hallum's publicly discussed target assumes. The required move of roughly 40% is very large, and it runs against a cautious sell-side backdrop in which the average target is near $4 and several analysts hold prices below the current share price. The strengthened balance sheet and a cleaner focus on higher-growth diagnostics are real supports, but repeated guidance cuts, negative earnings, and unresolved volume trends are substantial obstacles. The wide $2-to-$8 range of analyst views reflects genuine uncertainty, and investors should weigh the upcoming earnings update and transaction details carefully rather than treating any single objective as a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
MYGN sees MACD Histogram just turned negative
MYGN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 35 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MYGN moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MYGN as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
MYGN broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
MYGN moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MYGN crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +6.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in 198 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 108 of 154 cases where MYGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.325) is normal, around the industry mean (63.909). P/E Ratio (-3.568) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.448) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. MYGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic and predictive medicine products
Industry MedicalSpecialties
Advertisement